Posted on

CDC is recommending a “pause” in the administration of the single-dose Johnson & Johnson COVID-19 vaccine

external content.duckduckgo 68

the staff of the Ridgewood blog

New Brunswick NJ, the CDC is recommending a “pause” in the administration of the single-dose Johnson & Johnson COVID-19 vaccine to investigate reports of potentially dangerous blood clots.

In a joint statement Tuesday, the Centers for Disease Control and Prevention and the Food and Drug Administration said they were investigating clots in six women that occurred 6 to 13 days after vaccination. The clots were observed in the sinuses of the brain along with reduced platelet counts — making the usual treatment for blood clots, the blood thinner heparin, potentially “dangerous.”

The following statement is attributed to Dr. Anne Schuchat, Principal Deputy Director of the CDC and Dr. Peter Marks, director of the FDA’s Center for Biologics Evaluation and Research

As of April 12, more than 6.8 million doses of the Johnson & Johnson (Janssen ) vaccine have been administered in the U.S. CDC and FDA are reviewing data involving six reported U.S. cases of a rare and severe type of blood clot in individuals after receiving the J&J vaccine. In these cases, a type of blood clot called cerebral venous sinus thrombosis (CVST) was seen in combination with low levels of blood platelets (thrombocytopenia). All six cases occurred among women between the ages of 18 and 48, and symptoms occurred 6 to 13 days after vaccination. Treatment of this specific type of blood clot is different from the treatment that might typically be administered. Usually, an anticoagulant drug called heparin is used to treat blood clots. In this setting, administration of heparin may be dangerous, and alternative treatments need to be given.

CDC will convene a meeting of the Advisory Committee on Immunization Practices (ACIP) on Wednesday to further review these cases and assess their potential significance. FDA will review that analysis as it also investigates these cases. Until that process is complete, we are recommending a pause in the use of this vaccine out of an abundance of caution. This is important, in part, to ensure that the health care provider community is aware of the potential for these adverse events and can plan for proper recognition and management due to the unique treatment required with this type of blood clot.

Right now, these adverse events appear to be extremely rare. COVID-19 vaccine safety is a top priority for the federal government, and we take all reports of health problems following COVID-19 vaccination very seriously. People who have received the J&J vaccine who develop severe headache, abdominal pain, leg pain, or shortness of breath within three weeks after vaccination should contact their health care provider. Health care providers are asked to report adverse events to the Vaccine Adverse Event Reporting System at https://vaers.hhs.gov/reportevent.htmlexternal icon.

6 thoughts on “CDC is recommending a “pause” in the administration of the single-dose Johnson & Johnson COVID-19 vaccine

  1. 6 blood clots in 6.8 million doses. Nothing to see here. Move along please.

  2. Political decision

  3. Noticed some people get bugged out after they get vaccinated

  4. 6 blood clots in 6.8 million doses.
    Far below the rate of death from COVID.
    The press has been waiting for something like this.
    Hysteria starts in 3…2…1

  5. somebody at JNJ forgot to make the payoff….

    …so now they are really paying.

  6. Guess what people it’s not a vaccination. It only last less than a year. Vaccinations last more than a year. They are only calling it. A vaccination.

    Don’t be a fool

Leave a Reply

Your email address will not be published. Required fields are marked *